Strategies for initiating combination antiretroviral therapy

AIDS Patient Care and STDs

Volumn 19, Issue 4, 2005, Pages 224-238

  Tapper, Michael L ^a   Daar, Eric S ^b   Piliero, Peter J ^c   Smith, Kimberly ^d   Steinhart, Corklin ^e,f  

^a LENOX HILL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e Mercy Hospital Miami   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; METHADONE; NEVIRAPINE; PROTEINASE INHIBITOR; RIBAVIRIN; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG POTENTIATION; DYSLIPIDEMIA; HEALTH CARE ORGANIZATION; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; JAUNDICE; LIPIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; LIVER TOXICITY; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; TERATOGENICITY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUIDELINES; HIV INFECTIONS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; PATIENT SELECTION; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 18144416175     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2005.19.224     Document Type: Review

References (79)

1. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, March 2004. Department of Health and Human Services. aidsinfo.nih.gov/ guidelines. (Last accessed October 29, 2004).
2. Tashima K, Staszewski S, Nelson M, et al. Durable viral suppression on EFV-based HAART: 168 weeks of follow-up [Abstract TuPeB4547], Program and Abstracts of the XV International AIDS Conference. Bangkok, Thailand: July 11-16, 2004.
3. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2304-2315.
4. Staszewski S, Gallant JE, Pozniak AL, et al. Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week preliminary interim results [Abstract 564b]. Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: February 10-14, 2003.
5. Miller MD, Margot NA, McColl DJ, Coakley DF, Cheng AK. Characterization of virologic failure through 96 weeks among treatment-naïve patients taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) [Abstract 553]. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
6. Lanier ER, Irlbeck D, Ross L, et al. Prediction of NRTI options by linking reverse transcriptase genotype to phenotypic breakpoints [Abstract 586]. Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: February 10-14, 2003.
7. Miller MD, Margot NA, McColl DJ, Coakley DF, Cheng AK. Characterization of virologic failure through 96 weeks among treatment-naïve patients taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) [Abstract 553]. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
8. DeJesus E, Herrera G, Teofilo E, et al. Efficacy and safety of abacavir (ABC) versus zidovudine (ZDV) in antiretroviral therapy naive adults with HIV-1 infection (Study CNA30024) [Abstract H-446]. Program and Abstracts of the 43rd ICAAC. Chicago, Illinois: September 14-17, 2003.
9. Gazzard BG, DeJesus E, Cahn P, et al. Abacavir (ABC) once daily (OAD) plus lamivudine (3TC) OAD in combination with efavirenz (EFV) OAD is well-tolerated and effective in the treatment of antiretroviral therapy (ART) naive adults with HIV-1 infection (ZODIAC Study: CNA30021) [Abstract H-1722b]. Program and Abstracts of the 43rd ICAAC. Chicago, Illinois: September 14-17, 2003.
10. Cahn P, Raffi F, Saag M, et al. Virologic efficacy and patterns of resistance mutations in ART-naive patients receiving combination therapy with once-daily emtricitabine compared to twice-daily stavudine in a randomized, double-blind, multicenter clinical trial [Abstract 606]. Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: February 10-14, 2003.
11. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results [Abstract 570]. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California: February 8-11, 2004.
12. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN study. Lancet 2004;363:1253-1263.
13. Bernstein B, Kempf D, King M, et al. Comparison of the emergence of resistance in a blinded phase III study with Kaletra™ (lopinavir/ ritonavir) or nelfinavir plus d4T/3TC from week 24 through week 96 [Abstract 1768]. Program and Abstracts of the 41st ICAAC. Chicago, Illinois: December 16-19, 2001.
14. Kempf D, King M, Bauer E, et al. Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir/ritonavir or nelfinavir as initial therapy [Abstract 600]. Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: February 10-14, 2003.
15. Kempf DF, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189:51-60.
16. Senne I, Cahn P, Percival L, et al. Comparative results (phase II 48-week): BMS232632, stavudine, lamivudine, as HAART for treatment-naive HIV (+) patients (AI424-008) [Abstract I-667]. Program and Abstracts of the 41st ICAAC. Chicago, Illinois: December 16-19, 2001.
17. Squires KE, Thiry A, Giordano M. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV + 3TC: Comparison of antiviral efficacy and safety through week 24 (AI424-034) [Abstract H-1076]. Program and Abstracts of the 42nd ICAAC. San Diego, California: September 27-30, 2003.
18. Taburet AM, Piketty C, Gerard L, et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: A sub-study of Puzzle2-ANRS 107 trial [Abstract 537]. Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts: February 10-14, 2003.
19. Kaul S, Bassi K, Damle B, et al. Pharmacokinetic (pk) evaluation of the combination of atazanavir (ATV), enteric-coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for once-daily antiretroviral regimen [Abstract A-1616]. Program and Abstracts of the 43rd ICAAC. Chicago, Illinois: September 14-17, 2003.
20. Dear Health Care Professional communication. August 2003. www.fda.gov/medwatch/SAFETY/safety03.htm#reyataz (Last accessed June 2004).
21. Colonno R, Rose R, Cianci C, Aldrovandi G, Parkin N, Friborg J. Emergence of atazanavir resistance and maintenance of susceptibility to other PIs is associated with I50L substitution in HIV protease [Abstract 597]. Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: February 10-14, 2003.
22. Nadler J, Rodriguez-French A, Millard J, Wannamaker P. The NEAT study: GW433908 efficacy and safety in ART-naïve subjects, final 48-week analysis [Abstract 177]. Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: February 10-14, 2003.
23. Schurmann D, Gathe J, Sanne I, Wood R, et al. Efficacy and safety of GW433908/ritonavir once daily in therapy naïve subjects, 48 week results: the SOLO study [Abstract PL14.4]. Program and Abstracts of the 6th International Congress on Drug Therapy in HIV Infection. Glasgow, UK: November 17-21, 2002.
24. Macmanus S, Yates P, White S, Richards N, Snowden W. GW433908 in ART-naïve subjects: Absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen [Abstract 598]. Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: February 10-14, 2003.
25. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350:1850-1861.
26. Nassar N, Armas L, Smillie J, Morena S, Keiser P. An observational cohort comparison of zidovudine-lamivudine-efavirenz to zidovudine-lamivudine-abacavir in antiretroviral-naive individuals [Abstract 554]. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
27. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine, and tenofovir in the treatment naïve HIV-infected patients [Abstract 43]. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
28. Gallant JE, Rodriguez AE, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis [Abstract H-17223]. Program and Abstracts of the 43rd ICAAC. Chicago, Illinois: September 14-17, 2003.
29. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment-naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF [Abstract 51]. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California: February 8-11, 2004.
30. Stern JO, Love JT, Robinson PA, et al. Hepatic safety of nevirapine: results of the Boehringer-Ingelheim Viramune® Hepatic Safety Project [Abstract LBOr15]. Program and Abstracts of the XIV International AIDS Conference. Barcelona, Spain: July 7-12, 2002.
31. Resiler K. High hepatotoxicity rate seen among HAART patients. AIDS Alert 2001;16:118-119.
32. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection. 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004;292:251-265.
33. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy, July 2003. www.bhiva.org (Last accessed June 2004).
34. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings, guidelines for a public health approach, 2002. who.int/docstore/hiv/scaling/guidelines.pdf (Last accessed June 2004).
35. Centers for Disease Control and Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2004;53:37.
36. Manosuthi W, Sungkanuparph, Vibhagool A, et al. A randomized controlled trial of efavirenz 600 mg/day versus 800 mg/day in HIV-infected patients with tuberculosis to study plasma efavirenz level, virological and immunological outcomes: a preliminary result [Abstract MoOrB1013]. Program and Abstracts of the XV International AIDS Conference. Bangkok, Thailand: July 11-16, 2004.
37. French government guidelines on HFV treatment. www.sante.gouv.fr/htm/ actu/delfraissy/index.htm (Last accessed June 2004).
38. British Columbia Center for Excellence in HIV/AIDS. The therapeutic guidelines for the treatment of HIV/AIDS and related conditions, cfeweb.hivnet. ubc.ca/guide/page/intro/intro.html (Last accessed June 2004).
39. New York State Department of Health AIDS Institute. Guidelines for antiretroviral treatment of HIV infection. www.hivguidelines.org/(Last accessed June 2004).
40. Little SJ, Holte S, Routy J-P, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
41. Vallecillo G, Knobel H, Guelar A, et al. Prevalence of osteopenia and osteoporosis in HIV-infected antiretroviral naïve patients [Abstract WePeB5871]. Program and Abstracts of the XV International AIDS Conference. Bangkok, Thailand: July 11-16, 2004.
42. Rivas P, Akasbi M, Gorgolas M, et al. Osteopenia and osteoporosis in antiretroviral naive patients with advanced AIDS [Abstract WePeB5967]. Program and Abstracts of the XV International AIDS Conference. Bangkok, Thailand: July 11-16, 2004.
43. Hung CC, Shih TTF, Chen MY, et al. Longitudinal followup study of bone mineral density of HIV-infected patients treated with highly active antiretroviral therapy [Abstract WePeB5860]. Program and Abstracts of the XV International AIDS Conference. Bangkok, Thailand: July 11-16, 2004.
44. Gallant J, Staszewski S, Pozniak AL, et al. Long-term efficacy and safety of tenofovir disoproxil fumarate (TDF): A 144-week comparison versus stavudine (d4T) in antiretroviral-naïve patients [Abstract TuPeB4538]. Program and Abstracts of the XV International AIDS Conference. Bangkok, Thailand: July 11-16, 2004.
45. Smith KY, Buruts A, Cathcart R, et al. Optimizing care for African-American HIV-positive patients. AIDS Patient Care STDs 2003;17:527-538.
46. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2002;14:1-40. www.cdc.gov/hiv/stats/hasrlink.htm. (Last accessed June 2004).
47. Crystal S, Sambamoorthi U, Moynihan PJ, McSpirtt E. Initiation and continuation of newer antiretroviral treatments among Medicaid recipients with AIDS. J Gen Intern Med 2001;16:850-859.
48. Welch KJ, Morse A. Survival patterns among HIV+ individuals based on health care utilization. J Natl Med Assoc 2001;93:214-219.
49. HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr 2002;30:21-26.
50. McNaghten A, Hanson D, Dworkin M. Differences in prescription of highly active antiretroviral therapy persist in 1999 [Abstract 494]. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois: February 4-8, 2001.
51. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: Longer follow-up of an observational cohort study. J Infect Dis 2003;188:1659-1665.
52. Ferguson TF, Stewart KE, Funkhouser E, Tolson J, Westfall AO, Saag MS. Patient-perceived barriers to antiretroviral adherence: Associations with race. AIDS Care 2002;14:607-617.
53. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 2001;26:82-92.
54. American Heart Association. Heart Disease and Stroke Statistics-2003 Update. Dallas, TX: American Heart Association, 2002.
55. National Institute of Diabetes and Digestive and Kidney Diseases, National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2003. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, 2003. diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm (Last accessed June 2004).
56. Schutt M, Meier M, Meyer M, Klein J, Aries SP, Klein HH. The HIV-1 protease inhibitor indinavir impairs insulin signaling in HepG2 hepatoma cells. Diabetologia 2000;43:1145-1148.
57. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002;16:859-863.
58. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15:F11-F18.
59. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study. AIDS 2002;16:F1-F8.
60. Martins D, Tareen N, Norris KC. The epidemiology of end-stage renal disease among African Americans. Am J Med Sci 2002;323:65-71.
61. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: A 12 year cohort study. AIDS 2004;18:541-546.
62. Freedman BI, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 1999;34:254-258.
63. Haas D, Ribaudo H, Kim R, et al. A common CYP2B6 variant is associated with efavirenz pharmacokinetics and central nervous system side effects: AACTG Study NWC5214 [Abstract 133]. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California: February 8-11, 2004.
64. Taylor S, Allen S, Fidler S, et al. Stop study: after discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer [Abstract 131]. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California: February 8-11, 2004.
65. Ribaudo H, Clifford D, Gulick R, et al. Relationships between pharmacokinetics, side effects, drug discontinuation, virologic response, and race: Results from ACTG A5095/A5097s [Abstract 132]. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California: February 8-11, 2004.
66. Cooper ER, Charurat M, Burns DN, Blattner W, Hoff R. Trends in antiretroviral therapy and mother-infant transmission of HIV. The Women and Infants Transmission Study Group. J Acquir Immune Defic Syndr 2000;24:45-47.
67. Perinatal HIV Guidelines Working Group. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States, November 26, 2003. Department of Health and Human Services. aidsinfo.nih.gov/ guidelines (Last accessed June 2004).
68. Dear Healthcare Professional communication. Clarification of risk factors for severe, life-threatening and fatal hepatotoxicity with nevirapine, February 2004. www.fda.gov/medwatch/SAFETY/2004/viramune_deardoc_Feb04.pdf (Last accessed June 2004).
69. Maruschak LM. HIV in Prisons. Bureau of Justice Statistics Bulletin. October 2000, NCJ 196023.
70. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health 2002;92:1789-1794.
71. Fischl M, Rodriguez A, Scerpella E, Monroig R, Thompson L, Rechtine D. Impact of directly observed therapy on outcomes in HIV clinical trials [Abstract 71]. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California: January 30-February 2, 2000.
72. Hammett TM, Harmon P, Rhodes W. The burden of infectious disease among inmates and releasees from correctional facilities. In: The Health Status of Soon-To-Be-Released Inmates: A Report to Congress, Vol. 2. Chicago: National Commission on Correctional Health Care, March 2002.
73. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002;288:199-206.
74. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003;138:197-207.
75. Maier I, Wu GY. Hepatitis C and HIV co-infection: A review. World J Gastoenterol 2002;8:577-579.
76. Altice FL, Mezger J, Hodges J, Bruce D, Springer S, Freidland GH. Directly observed therapy (DOT) for HIV+ drug users (IDUs) [Abstract 4O]. Program and Abstracts of the 2nd IAS Conference on Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
77. Altice FL, Mezger J, Hodges J, Bruce RD, Friedland GH. Special considerations for DOT programmes for HIV+ drug users [Abstract 660]. Program and Abstracts of the 2nd IAS Conference on Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
78. Lucas GM, Glexner CW, Moore RD. Directly administered antiretroviral therapy in the treatment of HIV infection: Benefit or burden? AIDS Patient Care STDS 2002;16:527-535.
79. Bangsberg DR, Mundy LM, Tulsky JP. Expanding directly observed therapy: Tuberculosis to human immunodeficiency virus. Am J Med 2001;110:664-666.